Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference 50c221e544
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
28 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Dapoxetine Hydrochloride Tablets 2 records · Latest accepted 2024/08/13
Generic · 2
Temozolomide For Injection 3 records · Latest accepted 2023/11/29
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2302623 | Supplement | 2023/11/29 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Guangdong Sunho Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2302577 | Supplement | 2023/11/22 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Guangdong Sunho Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2301699 | Supplement | 2023/07/29 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Guangdong Sunho Pharmaceutical Co., Ltd. | CDE ↗ |
Sildenafil Citrate Tablets 3 records · Latest accepted 2023/07/26
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301992 | Generic | 2023/07/26 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201973 | Generic | 2022/11/14 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201972 | Generic | 2022/11/14 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
Avanafil Tablets 3 records · Latest accepted 2023/07/11
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2301538 | Supplement | 2023/07/11 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2301537 | Supplement | 2023/07/11 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2301536 | Supplement | 2023/07/11 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
Metformin Hydrochloride And Empagliflozin Extended Release Tablets 4 records · Latest accepted 2023/05/17
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301339 | Generic | 2023/05/17 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2301338 | Generic | 2023/05/17 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2301337 | Generic | 2023/05/17 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2301336 | Generic | 2023/05/17 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
Tadalafil Tablets 3 records · Latest accepted 2023/04/28
Supplement · 1Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2300923 | Supplement | 2023/04/28 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2102033 | Generic | 2021/11/19 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2101582 | Generic | 2021/08/16 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
Sivelestat Sodium for Injection 2 records · Latest accepted 2023/04/11
New drug · 1Supplement · 1
Azilsartan and Amlodipine Tablets 1 records · Latest accepted 2022/08/17
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHL2200066 | Generic | 2022/08/17 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
Sugammadex Sodium Injection 2 records · Latest accepted 2022/08/01
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201201 | Generic | 2022/08/01 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHS2201200 | Generic | 2022/08/01 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | CDE ↗ |
Esomeprazole Sodium for Injection 2 records · Latest accepted 2022/06/29
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2201057 | Supplement | 2022/06/29 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2201056 | Supplement | 2022/06/29 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Tenofovir Disoproxil Fumarate Tablets 1 records · Latest accepted 2021/11/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2102178 | Supplement | 2021/11/25 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
Levoleucovorin for Injection 2 records · Latest accepted 2021/05/06
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2101018 | Supplement | 2021/05/06 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Suzhou Di Yi Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CXHB2101017 | Supplement | 2021/05/06 | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized; Suzhou Di Yi Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Catalogue holder records
23 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Dapoxetine Hydrochloride Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20256001 | 2025/11/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapoxetine Hydrochloride Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20256000 | 2025/11/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20244459 | 2024/07/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sugammadex Sodium Injection | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | 国药准字H20243562 | 2024/04/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20243514 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20243513 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20247036 | 2024/02/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20233235 | 2023/02/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tadalafil Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20233240 | 2023/02/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Esomeprazole Sodium for Injection | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | 国药准字H20203096 | 2022/03/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Esomeprazole Sodium for Injection | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized | 国药准字H20227040 | 2022/03/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Temozolomide For Injection | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20213724 | 2021/09/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Silodosin Capsules | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20213612 | 2021/07/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Azacitidine For Injection | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20213493 | 2021/06/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dienogest Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Nanjing Bai Jing Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20213439 | 2021/06/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Avanafil Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20213338 | 2021/05/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Avanafil Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20213337 | 2021/05/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Avanafil Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20213336 | 2021/05/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20203740 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20203739 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20203738 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tenofovir Disoproxil Fumarate Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20193433 | 2019/12/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ticagrelor Tablets | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | 国药准字H20193252 | 2019/09/05 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
13 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 瑞卢戈利 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20260000272 | I | 2026/04/22 | CDE ↗ |
| 枸橼酸西地那非 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20240000285 | A | 2025/07/31 | CDE ↗ |
| JC242 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20240000042 | I | 2024/01/29 | CDE ↗ |
| 舒更葡糖钠 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20220000464 | A | 2026/01/06 | CDE ↗ |
| 赛洛多辛 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20200000376 | A | 2026/10/21 | CDE ↗ |
| HTMC0435 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20190001126 | I | 2019/12/16 | CDE ↗ |
| 西维来司他钠 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20190001060 | A | 2026/10/21 | CDE ↗ |
| 富马酸替诺福韦二吡呋酯 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20190006796 | A | 2023/03/24 | CDE ↗ |
| 阿伐那非 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20190000743 | A | 2025/12/03 | CDE ↗ |
| 替莫唑胺 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20180001446 | A | 2026/05/22 | CDE ↗ |
| 阿扎胞苷 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20180000608 | A | 2026/04/04 | CDE ↗ |
| 左亚叶酸 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20180001732 | A | 2026/03/21 | CDE ↗ |
| 艾司奥美拉唑钠 · No verified English name | Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | Y20170001052 | A | 2023/11/23 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
9 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Relugolix Tablets | CYHS2601163 | Generic | 2026/05/18 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| 恩格列净二甲双胍缓释片(III) · No verified English name | CYHB2500494 | Supplement | 2025/03/12 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| 恩格列净二甲双胍缓释片(II) · No verified English name | CYHB2500493 | Supplement | 2025/03/12 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| 恩格列净二甲双胍缓释片(I) · No verified English name | CYHB2500492 | Supplement | 2025/03/12 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| Azilsartan and Amlodipine Tablets | CYHS2402787 | Generic | 2024/08/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| Metformin Hydrochloride And Empagliflozin Extended Release Tablets | CYHB2401229 | Supplement | 2024/08/09 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| Avanafil Tablets | CYHB2202295 | Supplement | 2022/12/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| Avanafil Tablets | CYHB2202294 | Supplement | 2022/12/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
| Avanafil Tablets | CYHB2202293 | Supplement | 2022/12/27 | Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Hui Lun Jiangsu Pharma Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.